DK1553953T3 - Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucom - Google Patents

Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucom

Info

Publication number
DK1553953T3
DK1553953T3 DK03758746.6T DK03758746T DK1553953T3 DK 1553953 T3 DK1553953 T3 DK 1553953T3 DK 03758746 T DK03758746 T DK 03758746T DK 1553953 T3 DK1553953 T3 DK 1553953T3
Authority
DK
Denmark
Prior art keywords
composition
glaucoma
treatment
latanoprost
ocular hypertension
Prior art date
Application number
DK03758746.6T
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag Usa Inc filed Critical Sucampo Ag Usa Inc
Application granted granted Critical
Publication of DK1553953T3 publication Critical patent/DK1553953T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Solid Thermionic Cathode (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
DK03758746.6T 2002-10-24 2003-10-22 Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucom DK1553953T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42077602P 2002-10-24 2002-10-24
US42104402P 2002-10-25 2002-10-25
US10/429,677 US7074827B2 (en) 2002-10-24 2003-05-06 Method for treating ocular hypertension and glaucoma
PCT/JP2003/013452 WO2004037267A1 (en) 2002-10-24 2003-10-22 Method and composition containing latanoprost for treating ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
DK1553953T3 true DK1553953T3 (da) 2010-10-25

Family

ID=32110845

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03758746.6T DK1553953T3 (da) 2002-10-24 2003-10-22 Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucom

Country Status (9)

Country Link
US (2) US7074827B2 (da)
EP (2) EP2253322A1 (da)
JP (2) JP2006503913A (da)
AT (1) ATE480240T1 (da)
AU (1) AU2003274734A1 (da)
CA (1) CA2502437C (da)
DE (1) DE60334134D1 (da)
DK (1) DK1553953T3 (da)
WO (1) WO2004037267A1 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1667705A1 (en) * 2003-10-03 2006-06-14 Allergan, Inc. Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
DE102005035986B4 (de) * 2005-07-28 2009-10-15 Bausch & Lomb Incorporated Steriles tropfbares mehrphasiges emulgatorfreies ophthalmisches Präparat
PL1937212T3 (pl) * 2005-10-10 2011-02-28 Santen Sas Emulsje oftalmiczne zawierające prostaglandyny
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
AU2007304996B2 (en) * 2006-09-28 2013-03-21 Novartis Ag Self-preserved aqueous pharmaceutical compositions
FR2912207B1 (fr) * 2007-02-01 2012-10-26 Air Liquide Procede et appareil de production de monoxyde de carbone par distillation cryogenique
EP2123278B1 (en) * 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Eye drop preparation comprising latanoprost
JP2008247828A (ja) * 2007-03-30 2008-10-16 Wakamoto Pharmaceut Co Ltd ラタノプロストを含有する水性医薬組成物。
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
JP2009040727A (ja) * 2007-08-09 2009-02-26 Towa Yakuhin Kk ラタノプロストを有効成分とする安定な点眼液剤
WO2009028674A1 (ja) * 2007-08-29 2009-03-05 Wakamoto Pharmaceutical Co., Ltd. ラタノプロスト含有水性医薬組成物
MX2007011165A (es) * 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
ES2443548T5 (es) * 2008-03-17 2020-01-23 Alcon Res Ltd Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
JP2010275259A (ja) * 2009-05-29 2010-12-09 Toa Yakuhin Kk 均一、かつ安定なラタノプロスト点眼液剤組成物
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
EP2269575A1 (en) 2009-06-30 2011-01-05 Santen Pharmaceutical Co., Ltd Method for improving bioavailability of latanoprost
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
SI3431074T1 (sl) * 2010-07-29 2022-07-29 Allergan, Inc. Raztopine bimatoprosta in timolola brez konzervansov
WO2012015996A2 (en) * 2010-07-29 2012-02-02 Allergan, Inc. Preservative free bimatoprost solutions
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
EP2452669A1 (en) 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CA2866067C (en) 2011-01-19 2015-04-21 Topokine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
JP6329130B2 (ja) * 2012-04-10 2018-05-30 アイノビア，インコーポレイティド 噴霧エジェクタ機構、電荷分離及び制御可能な液滴電荷を提供する装置、並びに低投与量の点眼
CN109011046B (zh) 2012-04-20 2021-10-01 艾诺维亚股份有限公司 用于向目标输送流体的装置
MX2014013853A (es) 2012-05-14 2015-08-06 Eyenovia Inc Dispositivo generador de gotas de flujo laminar y metodos de uso.
JP6240170B2 (ja) 2012-05-15 2017-11-29 アイノビア，インコーポレイティド エジェクタ装置，並びにその方法，ドライバ，及び回路
PL3181119T3 (pl) 2012-09-12 2020-01-31 Novaliq Gmbh Kompozycje semifluorowanych alkanów do zastosowania w leczeniu suchego zapalenia spojówki i rogówki
CN113679698B (zh) 2012-09-12 2022-07-26 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
CA2869676C (en) 2012-11-21 2015-06-23 Topokine Therapeutics, Inc. Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
NO2753788T3 (da) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
TW201542196A (zh) * 2013-08-26 2015-11-16 Rohto Pharma 眼科用製劑
GR1008483B (el) * 2013-12-23 2015-05-12 Rafarm Α.Ε.Β.Ε., Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
US10326270B2 (en) 2014-08-05 2019-06-18 Sony Corporation DC power transmission device, DC power reception device, and DC power transmission system
ES2803248T3 (es) 2015-09-30 2021-01-25 Novaliq Gmbh 2-perfluorohexil octano para administración oftálmica
CN111743882A (zh) 2015-09-30 2020-10-09 诺瓦利克有限责任公司 半氟化化合物和其组合物
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
ES2763121T3 (es) 2016-06-23 2020-05-27 Novaliq Gmbh Método de administración tópica
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
CA3036306C (en) 2016-09-23 2024-05-14 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US10993944B2 (en) 2019-08-07 2021-05-04 Aneira Pharma, Inc. Methods and compositions for the treatment of hair loss
JP2022120120A (ja) * 2022-06-13 2022-08-17 東亜薬品株式会社 眼科用水性組成物及びプロスタグランジンＦ２α誘導体の含量の低下を抑制する方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2721414B2 (ja) * 1988-09-06 1998-03-04 フアーマシア・アンド・アツプジヨン・アー・ベー 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
WO1997023225A1 (en) 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
JPH10259179A (ja) * 1996-09-19 1998-09-29 Santen Pharmaceut Co Ltd 多置換アリールオキシ基を有するプロスタグランジン類およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
SE0002211D0 (sv) 2000-06-13 2000-06-13 Synphora Ab Methods and compositions for prevention of myopia
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
ATE490761T1 (de) * 2000-09-13 2010-12-15 Santen Pharmaceutical Co Ltd Augentropfen
AR035541A1 (es) * 2000-11-13 2004-06-16 Pharmacia Ab Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio
US8549114B2 (en) * 2002-06-12 2013-10-01 Bladelogic, Inc. Method and system for model-based heterogeneous server configuration management
KR101027454B1 (ko) * 2002-08-23 2011-04-06 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 안정한 점안액
CA2707067C (en) 2002-09-09 2013-07-16 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient

Also Published As

Publication number Publication date
EP1553953B1 (en) 2010-09-08
ATE480240T1 (de) 2010-09-15
US20060205725A1 (en) 2006-09-14
DE60334134D1 (de) 2010-10-21
WO2004037267A1 (en) 2004-05-06
US7074827B2 (en) 2006-07-11
JP2012162570A (ja) 2012-08-30
CA2502437A1 (en) 2004-05-06
US8673973B2 (en) 2014-03-18
JP2006503913A (ja) 2006-02-02
EP1553953A1 (en) 2005-07-20
EP2253322A1 (en) 2010-11-24
AU2003274734A1 (en) 2004-05-13
US20040082660A1 (en) 2004-04-29
CA2502437C (en) 2012-07-17

Similar Documents

Publication Publication Date Title
DK1553953T3 (da) Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucom
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE426413T1 (de) Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen
NO20052751L (no) Oftalmisk preparat for behandling av okulaer hypertensjon.
IS7215A (is) Aðferðir til að meðhöndla nýæðarsjúkdóma í augum
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
ECSP034815A (es) "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas"
DK1920764T4 (da) Fluprostenolisopropylester til anvendelse ved behandling af glaukom og okulær hypertension
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
WO2003047513A3 (en) Method for treating ocular hypertension
CY1108983T1 (el) Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων
WO2002009702A8 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
AU2003223224A8 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
IL160037A0 (en) Method and intra sclera implant for treatment of glaucoma and presbyopia
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
ES2172415A1 (es) Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
ATE375141T1 (de) Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer
ATE453395T1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
ATE223200T1 (de) Einen carboanhydrase-hemmer und xanthangummi enthaltendes augenarzneimittel
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
ATE216889T1 (de) Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension
DE69834638D1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
DE69912304D1 (de) Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen
NO20035043D0 (no) Fremgangsmåte for behandling av okular hypertensjon og glaukom